JP7399502B2 - びらん性変形性手関節症の治療のためのモンテルカスト - Google Patents

びらん性変形性手関節症の治療のためのモンテルカスト Download PDF

Info

Publication number
JP7399502B2
JP7399502B2 JP2021529734A JP2021529734A JP7399502B2 JP 7399502 B2 JP7399502 B2 JP 7399502B2 JP 2021529734 A JP2021529734 A JP 2021529734A JP 2021529734 A JP2021529734 A JP 2021529734A JP 7399502 B2 JP7399502 B2 JP 7399502B2
Authority
JP
Japan
Prior art keywords
montelukast
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021529734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022508236A (ja
JP2022508236A5 (enExample
Inventor
ホルディ、モンフォルト、ファウレ
ホセプ、ベルゲス、ミラノ
フェルナンド、ガルシア、アロンソ
ホルディ、ラメントル、マッサナ
ホセ、アンヘル、サンチェス、ガルシア
ヌリア、サンツ、メネンデス
マルタ、ビカリオ、デ、ラ、トーレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmalider SA
Original Assignee
Farmalider SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalider SA filed Critical Farmalider SA
Publication of JP2022508236A publication Critical patent/JP2022508236A/ja
Publication of JP2022508236A5 publication Critical patent/JP2022508236A5/ja
Application granted granted Critical
Publication of JP7399502B2 publication Critical patent/JP7399502B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021529734A 2018-11-26 2019-11-25 びらん性変形性手関節症の治療のためのモンテルカスト Active JP7399502B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382851.6 2018-11-26
EP18382851 2018-11-26
PCT/EP2019/082425 WO2020109230A1 (en) 2018-11-26 2019-11-25 Montelukast for the treatment of erosive hand osteoarthritis

Publications (3)

Publication Number Publication Date
JP2022508236A JP2022508236A (ja) 2022-01-19
JP2022508236A5 JP2022508236A5 (enExample) 2022-12-06
JP7399502B2 true JP7399502B2 (ja) 2023-12-18

Family

ID=64665075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529734A Active JP7399502B2 (ja) 2018-11-26 2019-11-25 びらん性変形性手関節症の治療のためのモンテルカスト

Country Status (22)

Country Link
US (1) US12539296B2 (enExample)
EP (1) EP3886857B1 (enExample)
JP (1) JP7399502B2 (enExample)
CN (1) CN113347975B (enExample)
AU (1) AU2019386235B2 (enExample)
BR (1) BR112021009980A2 (enExample)
CA (1) CA3120920C (enExample)
DK (1) DK3886857T3 (enExample)
ES (1) ES2961390T3 (enExample)
FI (1) FI3886857T3 (enExample)
HR (1) HRP20231283T1 (enExample)
HU (1) HUE063579T2 (enExample)
MA (1) MA54276B1 (enExample)
MD (1) MD3886857T2 (enExample)
MX (1) MX2021006209A (enExample)
MY (1) MY203365A (enExample)
PL (1) PL3886857T3 (enExample)
PT (1) PT3886857T (enExample)
RS (1) RS64668B1 (enExample)
SI (1) SI3886857T1 (enExample)
TW (1) TWI850283B (enExample)
WO (1) WO2020109230A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230372324A1 (en) * 2020-10-13 2023-11-23 Diomed Developments Ltd. Gel formulations comprising montelukast
GB2599912B (en) * 2020-10-13 2023-04-19 Diomed Dev Ltd New formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540761A (ja) 2013-12-02 2016-12-28 アッヴィ・インコーポレイテッド 変形性関節症を治療するための組成物及び方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201020085D0 (en) * 2010-11-26 2011-01-12 Xaragen Pharma Ltd Methods and reagents for the treatment of arthritic disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540761A (ja) 2013-12-02 2016-12-28 アッヴィ・インコーポレイテッド 変形性関節症を治療するための組成物及び方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Annals of the Rheumatic Diseases，2018年12月，Vol.78, No.3，p.413-420
Cytokine，2018年01月，Vol.103，p.83-89
Osteoarthritis and Cartilage，2009年，Vol.17, Suppl.1，S282-S283
Osteoarthritis and Cartilage，2018年02月，Vol.26, No.7，p.880-887
免疫疾患の解説，大阪大学大学院医学系研究科呼吸器・免疫内科学ホームページ，2014年12月，http://www.imed3.med.osaka-u.ac.jp/disease/d-immu02-4.html

Also Published As

Publication number Publication date
PT3886857T (pt) 2023-10-25
AU2019386235B2 (en) 2024-11-21
TWI850283B (zh) 2024-08-01
CA3120920C (en) 2024-01-02
EP3886857A1 (en) 2021-10-06
SI3886857T1 (sl) 2023-12-29
MD3886857T2 (ro) 2023-12-31
HRP20231283T1 (hr) 2024-02-02
ES2961390T3 (es) 2024-03-11
EP3886857B1 (en) 2023-07-26
US20220047570A1 (en) 2022-02-17
MA54276A (fr) 2021-10-06
MA54276B1 (fr) 2023-11-30
JP2022508236A (ja) 2022-01-19
HUE063579T2 (hu) 2024-01-28
PL3886857T3 (pl) 2024-01-15
MX2021006209A (es) 2021-08-11
CA3120920A1 (en) 2020-06-04
BR112021009980A2 (pt) 2021-08-17
FI3886857T3 (fi) 2023-10-20
AU2019386235A1 (en) 2021-07-01
CN113347975A (zh) 2021-09-03
CN113347975B (zh) 2024-08-30
MY203365A (en) 2024-06-26
DK3886857T3 (da) 2023-10-09
TW202038954A (zh) 2020-11-01
US12539296B2 (en) 2026-02-03
RS64668B1 (sr) 2023-11-30
WO2020109230A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
CN117137912A (zh) 选择性s1p1受体激动剂的给药方案
ES2741146T3 (es) Formulaciones farmacéuticas de nitrio y sus usos
JP7754799B2 (ja) てんかん重積状態の治療に使用するためのガナキソロン
JP2007302657A (ja) 痙症の兆候および症候の緩和方法
JPH0920659A (ja) 炎症性腹部疾患のためのカッパ−アヘン製剤作働薬
JPWO2019098300A1 (ja) 放出制御製剤
KR20080105864A (ko) 리마프로스트를 함유하는 경추증의 치료 및/또는 증상 진전억제제
JP5828609B2 (ja) 持続性解熱鎮痛消炎剤
TWI850283B (zh) 用於治療糜爛性手部骨關節炎的孟魯司特
RU2809024C2 (ru) Монтелукаст для лечения эрозивного остеоартрита кистей рук
JP7366108B2 (ja) ロキソプロフェン又はその塩及びビタミンｂ１２類を含有する経口用医薬組成物
HK40054679A (en) Montelukast for the treatment of erosive hand osteoarthritis
HK40054679B (en) Montelukast for the treatment of erosive hand osteoarthritis
JP6042886B2 (ja) 早漏症治療用の薬学組成物
EP2146713B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
JPWO2005063253A1 (ja) アレルギー症状治療用医薬組成物
JPWO2005058878A1 (ja) 月経困難症の予防および／または治療剤
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
JP2008156232A (ja) リマプロストを含有してなる頚椎症の治療および／または症状進展抑制剤
JP2022540854A (ja) 疼痛を緩和するためのイブプロフェン及びトラマドールの組合せ
JP2009227669A (ja) 鼻閉抑制剤
BR112012030704B1 (pt) Composição farmacêutica de cocristais e processo para sua produção
JPWO2005058879A1 (ja) 滲出性中耳炎の予防および／または治療剤
JP2019073450A (ja) 慢性的な関節痛用の内服治療剤
HK1064036B (en) Kapp-opiate agonists for the treatment of bladder dieseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221125

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231129

R150 Certificate of patent or registration of utility model

Ref document number: 7399502

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150